This study evaluated the correlation of single nucleotide polymorphisms interleukin (IL)-10-592 and -1082 with hepatitis B virus (HBV) susceptibility and recovery. Total 190 chronic hepatitis B (CHB) patients, 81 individuals with self-limited HBV infections and 81 normal controls from the first Hospital of Jilin University were recruited. The IL-10 polymorphisms were detected by polymerase chain reaction with restriction fragment length polymorphism (PCR–RFLP). The χ 2 test (p < 0.05) and Fisher’s exact test were separately performed to analyze and compare the genotype frequencies of IL-10-592 and -1082 among different groups. Furthermore, logistic regression analysis (p < 0.05) was conducted to determine the correlation of genotypes with HBV infection and recovery. Genotype A/A, A/C and C/C of IL-10-592 had been detected in the three groups. The frequencies of -592A separately were 55.56, 64.67 and 55.33 % in the three groups. Genotypes of IL-10-592 only had significant difference among the patients and normal controls (p = 0.021). Genotypes A/A, A/G and G/G of IL-10-1082 were detected in CHB patients and individuals with self-limited HBV infection; however, genotype G/G had not been detected in normal controls. The frequencies of -1082G separately were 3.68, 6.17 and 11.11 % in the three groups. Genotypes of IL-10-1082 only had no significant difference among the patients and individuals with self-limited HBV infections (p = 0.130). We found that their risks of HBV infection existed significant difference. The IL-10-592 and -1082 polymorphisms might be associated with HBV infection, but not with the recovery after HBV infection.
Background: Digital health technologies have potential to address the challenges associated with traditional cardiac rehabilitation (CR). However, it is not complete enough for prescribed exercise guidance and remote monitoring. Objective: We aimed to evaluate the feasibility of a smartphone app for prescribed exercise tutoring by exercise videos combined with wearable devices to monitor heart rate in patients with stable coronary heart disease (CHD). Methods: The study is a quasi-experimental design study with a single group. A total of 31 patients were included with an average age of 56.2 years (SD 13.4). They participated in a 12-week remote digital CR program. We employed a wearable heart rate monitoring device connected with an app to monitor the patients’ exercise intensity. The app can display the videos corresponding to an exercise prescription to guide the exercise. Cardiorespiratory endurance, blood pressure, blood glucose, cholesterol, blood uric acid, left ventricular ejection fraction and quality of life (QoL) were assessed at the beginning and end of the intervention. Compliance and safety events were recorded as well. Results: Completion rate reached 90.3%. Average daily effective exercise time was 39.4 min (SD 17.8), and 92.9% of the patients could exercise in the prescribed intensity for at least 20 min per day. Average effective exercise days per week were 4.6 days (SD 2.2), and 67.9% of the patients could exercise in the prescribed intensity for at least 3 days per week. Patients’ peak VO2 ( P = 0.041) and peak metabolic equivalents ( P = 0.018) were significantly increased, low-density lipoprotein ( P = 0.036) and diastolic blood pressure at rest ( P = 0.044) were significantly decreased, and depression (GAD-7, P = 0.014) and anxiety (PHQ-9, P = 0.013) were significantly improved. Conclusions: It is feasible, safe, and helpful for stable CHD patients to use the app for prescribed exercise tutoring with videos combined with wearable devices to monitor heart rate. Trial Registration: ChiCTR1800019144.
Acinetobacter baumannii (A. baumannii), a very common pathogen, poses a significant public health threat due to its antibiotic resistance and long survival in healthcare environments. Both A. baumannii and carbapenem-resistant A. baumannii (CRAB) can spread through the air, increasing infection risks. Therefore, monitoring their presence in the air is of great significance, especially in hospitals. Herein, we developed a Chelex-100-LAMP-CRISPR/Cas12a (CLC) platform including DNA release and nucleic acid test. Combined with a wet cyclone sampler, the platform can detect airborne A. baumannii and its most common carbapenem-resistant gene, blaOXA-23, within 70 min. This CLC platform has also been proven to have a detection limit of 6 × 102 CFU of CRAB per test through simulated air samples. Moreover, this platform was also used to test five actual air samples from a tertiary hospital, and the results achieved perfect concordance with sequencing data, validating the platform’s accuracy and reliability. Therefore, the CLC platform showed great potential for the rapid, on-site detection of airborne A. baumannii and its carbapenem-resistant gene blaOXA-23, offering a valuable tool for infection control in healthcare environments.
In many research fields, the demand for miniaturized laser-induced fluorescence (LIF) detection systems has been increasing. This work has developed a compact LIF detector, employing a laser diode as the excitation source and a photodiode as the photodetector with an adjustable laser focal spot, to meet the diverse requirements of various observation targets, such as capillaries, PCR tubes, and microfluidic chips. It features the functionalities of background fluorescence correction, the adaptive adjustment of the dynamic range, and constant power control for the laser. The influence of the excitation power on the detection limit was studied through experiments, and the configuration results for LED/LD as light sources and 487/450 nm wavelengths were compared and optimized. A fully integrated, compact, modular epifluorescence LIF detector was subsequently constructed, measuring 40 × 22 × 38 mm3 in total size, with a cost of USD 320, and achieving a detection limit of 0.4 nM for fluorescein sodium. Finally, the detector was integrated into a nucleic acid detection system with a microfluidic chip on the Chinese Space Station (CSS) and was also tested with PCR tubes and capillaries, proving its broad practicality and adaptability to various analytical systems.
Entamoeba histolytica is a parasite that could cause severe amebiasis, an extremely contagious parasitic disease with critical clinical symptoms. Timely diagnosis and treatment of E. histolytica are crucial for preventing complications and fatalities. However, current methods for E. histolytica diagnosis still rely on traditional and laborious methods such as stool examinations and serological immunoassay. Those methods urgently need improved diagnostic sensitivity, diagnostic specificity, detection time, and diagnostic accuracy. Herein, we developed a rapid and accurate gradient-based digital immunoassay system for diagnosing E. histolytica. This method uses a homemade pre-coated recombinant Igl-C fragment with high binding affinity, designed, recombinantly expressed, and purified by our lab on a one-shot observation microfluidic chip to capture the disease biomarker, specific anti-Igl-C antibodies in the serum. The captured antibodies are detected by anti-human IgG-coated gold nanoparticles, forming a digital binding sandwich immunocomplex. After simple imaging processing, the number of gold nanoparticles bound to the reaction surface within the same field of view of the microscope image was analyzed. Then, it can be easily determined in about 15 min whether specific anti-Igl-C antibodies are in the serum, allowing quicker identification of E. histolytica infection. The detection and diagnosis performance were confirmed by testing 25 clinical serum samples. The novel diagnostic method provided a digital immunoassay platform and has a strong potential to be a high-efficiency tool for the clinical diagnosis of E. histolytica infection with heightened diagnostic sensitivity and diagnostic specificity. It offers the potential for rapid point-of-care testing, facilitating prompt treatment initiation and improved patient outcomes in resource-limited healthcare settings, making it a valuable asset in the fight against amebiasis.